Hence, the data from IL‐4R KO mice and the data from tuberculosis strongly suggest that both direct tumor killing and an adjuvant immunomodulatory activity are responsible for the DABIL‐4‐mediated therapeutic benefit. This evidence concerns the gene IL4R and tuberculosis.